Oxford-AstraZeneca announced the results after the early human trial of the coronavirus vaccine, ‘ChAdOx1 nCoV-19’. The results of observatory data from phase I/II of the vaccine trials are extremely encouraging and generate immunity against the novel coronavirus. Vaccine has also cleared safety trial for human use. Phase III trial is ongoing, and is expected to begin in India in the coming months.
Trials involving 1,077 people showed the injection led to them generate antibodies and T-cells that against coronavirus.
AstraZeneca has been given the license to produce Oxford’s potential coronavirus vaccine. Additionally, there have been reports that the vaccine developed by Oxford’s Jenner Institute has shown extremely promising results in the development of ‘double protection’ against coronavirus.
The Trump administration awarded the duo up to $1.2 billion from the Biomedical Advanced Research and Development Authority (BARDA) as part of Operation Warp Speed, the administration’s push to have a widely available coronavirus vaccine by January.
The vaccine candidate was developed within 3 months by the Jenner Institute of the Oxford University and has been made using the genetic material of the spike protein of SARS-Cov-2 combined with weakened adenovirus. Currently, Phase III trials of the AZD1222 are being conducted in Brazil on thousands of volunteers to understand the safety and efficacy of the vaccine candidate. On the other hand, Serum Institute of India, which is the largest vaccine manufacturer of the world by volume, has teamed with UK drug maker AstraZeneca to manufacturer 1 billion doses of COVID vaccine.